Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC15 protein, SIM0613 is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs. Read More
Recent Posts
Tepco to Restart Japan’s Biggest Nuclear Plant in January
South Korea, US Seek New Deal to Cooperate on Nuclear Submarines
India’s Sanction-Hit Nayara Delays Oil Refinery Maintenance Work
Asian markets are mixed after the S&P 500 hits record high, buoyed by strong US economic data
Igor Makarov’s ARETI International Group Reinforces Its Commitment to Cycling at the Mayflower Gran Prix Cyprus 2025
Toshiba Releases High-Speed Response, Full Input/Output Range CMOS Dual Comparator Suitable for Overcurrent Detection in Industrial Equipment
How can E. coli survive in frozen and microwaved Pillsbury Pizza Pops?
Faircourt Asset Management Inc. Announces December Distribution
Canterra Minerals Closes $5.7M Flow-Through Private Placement to Fund Exploration in Newfoundland
Bolivia lifts restrictions on satellite companies like Starlink to upgrade its internet connectivity
